Vitrolife´s CEO sells a portion of his shareholding
Vitrolife's CEO Thomas Axelsson has today sold 38,300 shares worth SEK 18.7 million. The remaining number of shares amounts to 13,000 shares.
"The Vitrolife share has developed very positively since I acquired the shares in 2012 and I therefore choose to realize part of the profit for private financial reasons," says Thomas Axelsson, CEO of Vitrolife AB. The transaction will be reported to The Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations.
Gothenburg, December 7, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.50 am CET on December 7, 2021.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women’s health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/